TABLE D.1 - CARDIOVASCULAR
Medications | EMT | EMT-IV | AEMT | EMT-I | P |
Anti-arrhythmic - Amiodarone - continuous infusion | N | N | N | Y | Y |
Anti-arrhythmic - Lidocaine - continuous infusion | N | N | N | Y | Y |
Anticoagulant - Glycoprotein inhibitors | N | N | N | N | Y |
Anticoagulant - Heparin (unfractionated) | N | N | N | N | Y |
Anticoagulant - Low Molecular Weight Heparin (LMWH) | N | N | N | N | Y |
Diltiazem | N | N | N | N | Y |
Dobutamine | N | N | N | N | N |
Dopamine - Monitoring and Maintenance | N | N | N | N | Y |
Epinephrine - infusion | N | N | N | N | Y |
Nicardipine | N | N | N | N | Y |
Nitroglycerin, intravenous | N | N | N | N | Y |
Norepinephrine | N | N | N | N | Y |
Thrombolytics - Monitoring and Maintenance | N | N | N | N | Y |
TABLE D.2 - HIGH RISK OBSTETRICAL PATIENTS
Medications | EMT | EMT-IV | AEMT | EMT-I | P |
Magnesium sulfate | N | N | N | N | Y |
Oxytocin - infusion | N | N | N | N | Y |
TABLE D.3 - INTRAVENOUS SOLUTIONS
Medications | EMT | EMT-IV | AEMT | EMT-I | P |
Monitoring and maintenance of hospital/medical facility initiated crystalloids | N | Y | Y | Y | Y |
Monitoring and maintenance of hospital/medical facility initiated colloids (non-blood component) infusions | N | N | N | Y | Y |
Monitoring and maintenance of hospital/medical facility initiated blood component infusion | N | N | N | N | Y |
Initiate hospital/medical facility supplied blood component infusions | N | N | N | N | Y |
Total parenteral nutrition (TPN) and/or vitamins | N | N | N | Y | Y |
TABLE D.4 - MISCELLANEOUS
Medications | EMT | EMT-IV | AEMT | EMT-I | P |
Antibiotic infusions | N | N | N | Y | Y |
Antidote infusion - Sodium bicarbonate infusion | N | N | N | N | Y |
Antiviral infusion | N | N | N | Y | Y |
Electrolyte infusion - Magnesium sulfate | N | N | N | N | Y |
Electrolyte infusion - Potassium chloride | N | N | N | N | Y |
Insulin | N | N | N | N | Y |
Mannitol | N | N | N | N | Y |
Methylprednisolone - infusion | N | N | N | N | Y |
Octreotide | N | N | N | N | Y |
Pantoprazole | N | N | N | N | Y |
6 CCR 1015-3-2-D